Q1/FY2023 FINANCIAL RESULTS
ENDED JUNE 30, 2024

from the beginning

Q1/FY2024 FINANCIAL RESULTS ENDED JUNE 30, 2024

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

I. Q1/FY2024 Consolidated Financial Results

• Q1/FY2024 FINANCIAL RESULTS: OVERVIEW

• Q1/FY2024 FINANCIAL RESULTS

• Q1/FY2024 FINANCIAL RESULTS: XTANDI AND STRATEGIC BRANDS

• PADCEV & VEOZAH: BUSINESS UPDATE

• IZERVAY: BUSINESS UPDATE (US)

• Q1/FY2024 FINANCIAL RESULTS: COST ITEMS

II. Initiatives for Sustainable Growth

• XTANDI AND STRATEGIC BRANDS: FY2024 KEY EXPECTED EVENTS

• ZOLBETUXIMAB / VYLOY: LATEST STATUS

• PROGRESS IN FOCUS AREA APPROACH: CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

• Q1/FY2024 PROGRESS

APPENDIX

• XTANDI AND STRATEGIC BRANDS: POTENTIAL PEAK SALES (AS OF JUL 2024)

• Q1/FY2024 ACTUAL: FX RATE

• FY2024 FORECAST: FX RATE & FX SENSITIVITY

• BALANCE SHEET & CASH FLOW HIGHLIGHTS

• BALANCE OF BONDS AND BORROWINGS HIGHLIGHTS

• MAIN INTANGIBLE ASSETS (AS OF JUN30, 2024)

• CAPITAL ALLOCATION

• CORE BASIS PERFORMANCE: CHANGES IN DEFINITIONS AND CONTEXT

• ENFORTUMAB VEDOTIN (EV): STUDY DATA IN SOLID TUMORS OTHER THAN UC (EV-202)

• ROBUST PIPELINE OF ASTELLAS

• PROGRESS IN OVERALL PIPELINE

• XTANDI AND STRATEGIC BRANDS: STATUS UPDATE

• ENZALUTAMIDE (1/2): ANDROGEN RECEPTOR INHIBITOR

• ENZALUTAMIDE (2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

• ENFORTUMAB VEDOTIN (EV) (1/4): NECTIN-4 TARGETED ADCOVERALL UC PROGRAM

• ENFORTUMAB VEDOTIN (EV) (2/4): CLINICAL STUDIES

• ENFORTUMAB VEDOTIN (EV) (3/4): STUDY DATA BY DISEASE STAGE OF UC

• ENFORTUMAB VEDOTIN (EV) (4/4): FUTURE OUTLOOK

• GILTERITINIB: FLT3 INHIBITOR

• ZOLBETUXIMAB: ANTI-CLAUDIN 18.2 MONOCLONAL ANTIBODY

• FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

• AVACINCAPTAD PEGOL (ACP): COMPLEMENT C5 INHIBITOR / PEGYLATED RNA APTAMER

• ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8

• Questions 9